Skip to main content
Erschienen in: Pathology & Oncology Research 2/2017

21.09.2016 | Original Article

Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer

verfasst von: Pengfei Liu, Wenhua Jiang, Shiyong Zhou, Jun Gao, Huilai Zhang

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is a common malignancy in women and contribute largely to the cancer related death. The purpose of this study is to confirm the roles of GATA3 and identify potential biomarkers of breast cancer. Chromatin Immunoprecipitation combined with high-throughput sequencing (ChIP-Seq) (GSM1642515) and gene expression profiles (GSE24249) were downloaded from the Gene Expression Omnibus (GEO) database. Bowtie2 and MACS2 were used for the mapping and peak calling of the ChIP-Seq data respectively. ChIPseeker, a R bioconductor package was adopted for the annotation of the enriched peaks. For the gene expression profiles, we used affy and limma package to do normalization and differential expression analysis. The genes with fold change >2 and adjusted P-Value <0.05 were screened out. Besides, BETA (Binding and Expression Target Analysis) was used to do the combined analysis of ChIP-Seq and gene expression profiles. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used for the functional enrichment analysis of overlapping genes between the target genes and differential expression genes (DEGs). What’s more, the protein-protein interaction (PPI) network of the overlapping genes was obtained through the Human Protein Reference Database (HPRD). A total of 46,487 peaks were identified for GATA3 and out of which, 3256 ones were found to located at −3000 ~ 0 bp from the transcription start sites (TSS) of their nearby gene. A total of 236 down- and 343 up-regulated genes were screened out in GATA3 overexpression breast cancer samples compared with those in control. The combined analysis of ChIP-Seq and gene expression dataset showed GATA3 act as a repressor in breast cancer. Besides, 68 overlaps were obtained between the DEGs and genes included in peaks located at −3000 ~ 0 bp from TSS. Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to cancer progression and gene regulation were found to be enriched in those overlaps. In the PPI network, NDRG1, JUP and etc. were found to directly interact with large number of genes, which might indicate their important roles in the progression of breast cancer.
Literatur
1.
Zurück zum Zitat Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2016) Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. JNCCN 14(3):324–354PubMed Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2016) Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. JNCCN 14(3):324–354PubMed
2.
Zurück zum Zitat Pusztai L, Ladanyi A, Szekely B, Dank M (2016) Immunotherapy opportunities in breast cancer. Magyar onkologia 60(1):34–40PubMed Pusztai L, Ladanyi A, Szekely B, Dank M (2016) Immunotherapy opportunities in breast cancer. Magyar onkologia 60(1):34–40PubMed
3.
Zurück zum Zitat Liu D (2016) Tumor necrosis factor-alpha, a regulator and therapeutic agent on breast cancer. Curr Pharm Biotechnol 17(6):486–494CrossRefPubMed Liu D (2016) Tumor necrosis factor-alpha, a regulator and therapeutic agent on breast cancer. Curr Pharm Biotechnol 17(6):486–494CrossRefPubMed
4.
Zurück zum Zitat Maximiano S, Magalhaes P, Guerreiro MP, Morgado M (2016) Trastuzumab in the Treatment of Breast Cancer. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy doi:10.1007/s40259–016–0162-9 Maximiano S, Magalhaes P, Guerreiro MP, Morgado M (2016) Trastuzumab in the Treatment of Breast Cancer. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy doi:10.​1007/​s40259–016–0162-9
5.
Zurück zum Zitat Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, Venook A, Chen LM, Wright F, Hammer M, Schmidt BL, Levine J, Miaskowski C, Aouizerat BE (2016) Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer. Biological research for nursing doi:10.1177/1099800416629209 Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, Venook A, Chen LM, Wright F, Hammer M, Schmidt BL, Levine J, Miaskowski C, Aouizerat BE (2016) Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer. Biological research for nursing doi:10.​1177/​1099800416629209​
9.
Zurück zum Zitat Si W, Huang W, Zheng Y, Yang Y, Liu X, Shan L, Zhou X, Wang Y, Su D, Gao J, Yan R, Han X, Li W, He L, Shi L, Xuan C, Liang J, Sun L, Wang Y, Shang Y (2015) Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis. Cancer Cell 27(6):822–836. doi:10.1016/j.ccell.2015.04.011 CrossRefPubMed Si W, Huang W, Zheng Y, Yang Y, Liu X, Shan L, Zhou X, Wang Y, Su D, Gao J, Yan R, Han X, Li W, He L, Shi L, Xuan C, Liang J, Sun L, Wang Y, Shang Y (2015) Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis. Cancer Cell 27(6):822–836. doi:10.​1016/​j.​ccell.​2015.​04.​011 CrossRefPubMed
10.
11.
Zurück zum Zitat Dieci MV, Smutna V, Scott V, Yin G, Xu R, Vielh P, Mathieu MC, Vicier C, Laporte M, Drusch F, Guarneri V, Conte P, Delaloge S, Lacroix L, Fromigue O, Andre F, Lefebvre C (2016) Whole exome sequencing of rare aggressive breast cancer histologies. Breast Cancer Res Treat 156(1):21–32. doi:10.1007/s10549–016-3718-y CrossRefPubMed Dieci MV, Smutna V, Scott V, Yin G, Xu R, Vielh P, Mathieu MC, Vicier C, Laporte M, Drusch F, Guarneri V, Conte P, Delaloge S, Lacroix L, Fromigue O, Andre F, Lefebvre C (2016) Whole exome sequencing of rare aggressive breast cancer histologies. Breast Cancer Res Treat 156(1):21–32. doi:10.​1007/​s10549–016-3718-y CrossRefPubMed
12.
Zurück zum Zitat Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE (2012) GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene 31(16):2017–2027. doi:10.1038/onc.2011.382 CrossRefPubMed Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE (2012) GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene 31(16):2017–2027. doi:10.​1038/​onc.​2011.​382 CrossRefPubMed
14.
Zurück zum Zitat Langmead B (2010) Aligning short sequencing reads with Bowtie. Current protocols in bioinformatics / editoral board, Andreas D Baxevanis [et al] Chapter 11:Unit 11 17. doi:10.1002/0471250953.bi1107s32 Langmead B (2010) Aligning short sequencing reads with Bowtie. Current protocols in bioinformatics / editoral board, Andreas D Baxevanis [et al] Chapter 11:Unit 11 17. doi:10.​1002/​0471250953.​bi1107s32
18.
Zurück zum Zitat Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4(5):P3 Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4(5):P3
19.
Zurück zum Zitat Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A (2009) Human Protein Reference Database--2009 update. Nucleic Acids Res 37(Database issue):D767–D772. doi:10.1093/nar/gkn892 CrossRefPubMed Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A (2009) Human Protein Reference Database--2009 update. Nucleic Acids Res 37(Database issue):D767–D772. doi:10.​1093/​nar/​gkn892 CrossRefPubMed
20.
22.
Zurück zum Zitat Li C, Deng L, Zhi Q, Meng Q, Qian A, Sang H, Li X, Xia J (2016) MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer. Anti Cancer Agents Med Chem 16(4):447–455CrossRef Li C, Deng L, Zhi Q, Meng Q, Qian A, Sang H, Li X, Xia J (2016) MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer. Anti Cancer Agents Med Chem 16(4):447–455CrossRef
23.
25.
Zurück zum Zitat Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, Harkin DP, Mullan PB (2012) BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene 31(32):3667–3678. doi:10.1038/onc.2011.531 CrossRefPubMed Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, Harkin DP, Mullan PB (2012) BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene 31(32):3667–3678. doi:10.​1038/​onc.​2011.​531 CrossRefPubMed
26.
Zurück zum Zitat Xiong Y, Castro E, Yagi R, Zhu J, Lesourne R, Love PE, Feigenbaum L, Bosselut R (2013) Thpok-independent repression of Runx3 by Gata3 during CD4+ T-cell differentiation in the thymus. Eur J Immunol 43(4):918–928. doi:10.1002/eji.201242944 CrossRefPubMed Xiong Y, Castro E, Yagi R, Zhu J, Lesourne R, Love PE, Feigenbaum L, Bosselut R (2013) Thpok-independent repression of Runx3 by Gata3 during CD4+ T-cell differentiation in the thymus. Eur J Immunol 43(4):918–928. doi:10.​1002/​eji.​201242944 CrossRefPubMed
27.
Zurück zum Zitat Liu W, Yue F, Zheng M, Merlot A, Bae DH, Huang M, Lane D, Jansson P, Lui GY, Richardson V, Sahni S, Kalinowski D, Kovacevic Z, Richardson DR (2015) The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget 6(11):8851–8874. doi:10.18632/oncotarget.3316 CrossRefPubMedPubMedCentral Liu W, Yue F, Zheng M, Merlot A, Bae DH, Huang M, Lane D, Jansson P, Lui GY, Richardson V, Sahni S, Kalinowski D, Kovacevic Z, Richardson DR (2015) The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget 6(11):8851–8874. doi:10.​18632/​oncotarget.​3316 CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Salis O, Bedir A, Kilinc V, Alacam H, Gulten S, Okuyucu A (2014) The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells. Cancer biomarkers: section A of Disease markers 14(6):419–426. doi:10.3233/CBM-140422 CrossRef Salis O, Bedir A, Kilinc V, Alacam H, Gulten S, Okuyucu A (2014) The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells. Cancer biomarkers: section A of Disease markers 14(6):419–426. doi:10.​3233/​CBM-140422 CrossRef
29.
Zurück zum Zitat Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW (2008) Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. International journal of gynecological cancer: official journal of the international gynecological cancer. Society 18(5):1051–1059. doi:10.1111/j.1525-1438.2007.01164.x Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW (2008) Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. International journal of gynecological cancer: official journal of the international gynecological cancer. Society 18(5):1051–1059. doi:10.​1111/​j.​1525-1438.​2007.​01164.​x
Metadaten
Titel
Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer
verfasst von
Pengfei Liu
Wenhua Jiang
Shiyong Zhou
Jun Gao
Huilai Zhang
Publikationsdatum
21.09.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0116-z

Weitere Artikel der Ausgabe 2/2017

Pathology & Oncology Research 2/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.